Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 10/20 | 0.48 |
| ▸ | ITGA4 | P13612 | 10/20 | 0.48 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.44 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | AR | P10275 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | PDE4A | P27815 | 1/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.42 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.42 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5068957 | 0.86 | CYP4F2 (0.44) | CYP4F2CYP4A11MAPTALDH1A1RAB9A | |
| SCHEMBL5069303 | 0.86 | ITGB1 (0.51) | ITGB1ITGA4CYP4F2CYP4A11 | |
| SCHEMBL8345876 | 0.86 | RAB9A (0.43) | ITGB1ITGA4MAPTALDH1A1RAB9A | |
| SCHEMBL8345075 | 0.86 | ITGB1 (0.45) | ITGB1ITGA4MAPTALDH1A1RAB9A | |
| SCHEMBL5068369 | 0.85 | RAB9A (0.45) | CYP4F2CYP4A11MAPTALDH1A1RAB9A | |
| SCHEMBL27614659 | 0.81 | ITGB1 (0.50) | ITGB1ITGA4 | |
| SCHEMBL14096923 | 0.81 | FNTA (0.42) | ITGB1ITGA4MAPTALDH1A1RAB9A | |
| SCHEMBL13991528 | 0.79 | CYP4F2 (0.64) | CYP4F2CYP4A11MAPTALDH1A1RAB9A | |
| SCHEMBL5068415 | 0.77 | ITGB1 (0.81) | ITGB1ITGA4 | |
| SCHEMBL5066936 | 0.75 | ITGB1 (0.52) | ITGB1ITGA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7410984-B2 | Compounds | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2008-08-12 | — | — | US | disclosed |
| US-20050288337-A1 | Novel compounds | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2005-12-29 | — | — | US | disclosed |
| EP-1539696-A2 | PROCESS FOR PREPARING QUINOLIN ANTIBIOTIC INTERMEDIATES | TANABE SEIYAKU CO., LTD. (JP) | 2005-06-15 | — | — | EP | disclosed |
| WO-2004014859-A2 | PROCESS FOR PREPARING QUINOLIN ANTIBIOTIC INTERMEDIATES | TANABE SEIYAKU CO., LTD. (JP) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288337-A1 | Novel compounds | ITGB4, ITGA4, ITGB5 | ITGB1 5/4885ITGA4 2/4885CYP4F2 1416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.